Xilio Therapeutics, Inc.

Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer. Its pipeline includes masked antibody-based therapies and other engineered biologics designed to activate in the tumor microenvironment, with development conducted through its wholly owned subsidiary, Xilio Development, Inc.

−92,4 %

−80,1 %

+589,9 %

2.58

2.58

— Xilio Therapeutics, Inc.
%
Tumor-activated cytokine therapies35% Engineered IL-12-based oncology programs designed to activate in tumors.
Masked T cell engagers30% Conditionally activated T cell engager molecules for cancer targets.
Masked antibody-based immunotherapies20% Antibody therapeutics designed to reduce systemic activity and improve selectivity.
Research and development collaborations15% Partnered discovery, development, and option agreements with pharma collaborators.

Xilio’s direct counterparties are pharmaceutical partners rather than end patients, since the company monetizes its...

  • Pharmaceutical collaboration partnersprimary

    Companies such as Gilead and AbbVie that license or option Xilio programs for development and commercialization.

  • Clinical trial ecosystemsecondary

    Hospitals, investigators, and trial networks that support testing of Xilio’s oncology candidates.

  • Future oncology treatment providersemerging

    Hospitals and cancer centers that would use approved therapies if any candidates reach market.

Xilio is headquartered in the United States and conducts its corporate and research activities from there...

  • •Headquartered and operated from the United States
  • •Collaborations grant global rights to partners
  • •Clinical and regulatory activity is driven by U.S. biotech infrastructure
  • •Commercial exposure is international through partner licenses
  • •No country-level revenue disclosure was provided

Xilio’s strategy is to advance tumor-activated immunotherapy assets while using partnerships to share development risk...

01
Expand and maintain strategic collaborationsshort-term

Partnerships provide funding, validation, and commercialization reach for early-stage assets.

02
Advance masked immunotherapy pipelinemedium-term

Clinical and preclinical progress is needed to create value and attract partners or approvals.

03
Secure capital to fund operationsshort-term

Early-stage biotech development requires external financing before product revenue exists.

Xilio is exposed to the execution risk typical of early-stage biotech companies: its programs may fail in preclinical...

critical

Financing and going-concern risk

The company needs substantial additional capital before product revenue is available.

Scope
Equity issuance, warrants, collaborations
Materiality
high
high

Partner dependence and limited control over partnered programs

Collaborators can decide whether and how quickly to advance licensed assets, affecting timing and value capture.

Scope
Gilead, AbbVie, Roche collaborations
Materiality
high
high

Clinical development failure

Early-stage oncology candidates may not show sufficient safety or efficacy.

Scope
Preclinical and clinical pipeline
Materiality
high
medium

Competitive pressure in oncology immunotherapy

Larger pharma and biotech firms may develop similar or superior therapies faster.

Scope
Masked biologics, T cell engagers, cytokine therapies
Materiality
medium
Fair value measurement of warrant liabilities
Common stock warrant liabilities
Collaboration and license accounting
Revenue and deferred revenue
Research and development expense estimation
Operating expenses
Going-concern assessment
Liquidity disclosures

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

BioXcel Therapeutics, Inc.

BTAI · Pharmaceutical Preparations

XBiotech Inc.

XBIT · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

SOLENO THERAPEUTICS INC

Pharmaceutical Preparations

: 29.4.2026